Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment

被引:7
作者
Dedemadi, Anastasia-Georgia [1 ,2 ]
Gkolfinopoulou, Christina [1 ]
Nikoleri, Dimitra [3 ,4 ]
Nikoloudaki, Myrto [3 ]
Ruhanen, Hanna [5 ,6 ,7 ]
Holopainen, Minna [5 ,6 ,7 ]
Kakela, Reijo [6 ,7 ]
Christopoulou, Georgia [8 ]
Bournazos, Stavros [8 ]
Constantoulakis, Pantelis [8 ]
Sidiropoulos, Prodromos [3 ,4 ]
Bertsias, George [3 ,4 ]
Chroni, Angeliki [1 ]
机构
[1] Natl Ctr Sci Res Demokritos, Inst Biosci & Applicat, Athens 15341, Greece
[2] Natl & Kapodistrian Univ Athens, Dept Chem, Athens, Greece
[3] Univ Crete, Med Sch, Lab Rheumatol Autoimmun & Inflammat, Iraklion, Greece
[4] FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece
[5] Univ Helsinki, Helsinki Inst Life Sci, Lipid Unit, HiLIPID, Helsinki, Finland
[6] Bioctr Finland, Helsinki, Finland
[7] Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Program, Helsinki, Finland
[8] Genotypos Sci Labs, Athens, Greece
关键词
systemic lupus erythematosus; biologicals; high-density lipoprotein; atheroprotection; lipidomic profile; CHOLESTEROL EFFLUX CAPACITY; ATHEROSCLEROSIS; FUNCTIONALITY;
D O I
10.1093/rheumatology/keae192
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Chronic inflammatory diseases, like Systemic Lupus Erythematosus (SLE), carry an increased risk for atherosclerosis and cardiovascular events, accompanied by impairment of atheroprotective properties of high-density lipoprotein (HDL). In SLE, serum B cell-activating factor (BAFF), a cytokine implicated in disease progression, has been correlated with subclinical atherosclerosis. We investigated the impact of treatment with belimumab -an anti-BAFF monoclonal antibody- on HDL atheroprotective properties and composition in SLE patients.Methods Serum samples were collected from 35 SLE patients with active disease despite conventional therapy, before and after 6-month add-on treatment with belimumab, and 26 matched healthy individuals. We measured cholesterol efflux and antioxidant capacities, paraoxonase-1 (PON1) activity, serum amyloid A1 (SAA1), myeloperoxidase (MPO) and lipid peroxidation product levels of HDL. LC-MS/MS was performed to analyse the HDL lipidome.Results Following treatment with belimumab, cholesterol efflux and antioxidant capacities of HDL were significantly increased in SLE patients and restored to levels of control subjects. HDL-associated PON1 activity was also increased, whereas lipid peroxidation products were decreased following treatment. HDL cholesterol efflux and antioxidant capacities correlated negatively with the disease activity. Changes were noted in the HDL lipidome of SLE patients following belimumab treatment, as well as between SLE patients and healthy individuals, and specific changes in lipid species correlated with functional parameters of HDL.Conclusions HDL of SLE patients with active disease displays impaired atheroprotective properties accompanied by distinct lipidomic signatures compared with controls. Belimumab treatment may improve the HDL atheroprotective properties and modify the HDL lipidomic signature in SLE patients, thus potentially mitigating atherosclerosis development. Graphical Abstract
引用
收藏
页码:648 / 657
页数:10
相关论文
共 50 条
[41]   Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus [J].
Bruce, Ian N. ;
Golam, Sarowar ;
Steenkamp, Jason ;
Wang, Pearl ;
Worthington, Evelyn ;
Desta, Barnabas ;
Psachoulia, Konstantina ;
Erhardt, Wilma ;
Tummala, Raj .
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (10) :765-777
[42]   Anti-high-density lipoprotein antibodies and lipoprotein characteristics in systemic lupus erythematosus-related cardiovascular disease [J].
J Su ;
A Cederholm ;
E Hurt-Camejo ;
E Svenungsson ;
J Frostegård .
Arthritis Research & Therapy, 7
[43]   Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus [J].
Schwarting, A. ;
Dooley, M. A. ;
Roth, D. A. ;
Edwards, L. ;
Thompson, A. ;
Wilson, B. .
LUPUS, 2016, 25 (14) :1587-1596
[44]   Anti-high-density lipoprotein antibodies and lipoprotein characteristics in systemic lupus erythematosus-related cardiovascular disease [J].
Su, J. ;
Cederholm, A. ;
Hurt-Camejo, E. ;
Svenungsson, E. ;
Frostegard, J. .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 1) :S40-S40
[45]   Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab: A case series [J].
Fan, Qiuyu ;
Yang, Huiqin ;
Liu, Ya .
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2024, 83 (05) :387-392
[46]   High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus [J].
Gaal, Krisztina ;
Tarr, Tuende ;
Lorincz, Hajnalka ;
Borbas, Viktor ;
Seres, Ildiko ;
Harangi, Mariann ;
Fueloep, Peter ;
Paragh, Gyoergy .
LIPIDS IN HEALTH AND DISEASE, 2016, 15
[47]   Impaired Antiatherogenic Functions of High-density Lipoprotein in Patients with Ankylosing Spondylitis [J].
Gkolfinopoulou, Christina ;
Stratikos, Efstratios ;
Theofilatos, Dimitris ;
Kardassis, Dimitris ;
Voulgari, Paraskevi V. ;
Drosos, Alexandros A. ;
Chroni, Angeliki .
JOURNAL OF RHEUMATOLOGY, 2015, 42 (09) :1652-1660
[48]   Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus [J].
Arends, Eline J. ;
Zlei, Mihaela ;
Tipton, Christopher M. ;
Cotic, Jasna ;
Osmani, Zgjim ;
de Bie, Fenna J. ;
Kamerling, Sylvia W. A. ;
van Maurik, Andre ;
Dimelow, Richard ;
Gregan, Yun Irene ;
Fox, Norma Lynn ;
Rabelink, Ton J. ;
Roth, David A. ;
Sanz, Ignacio ;
van Dongen, Jacques J. M. ;
van Kooten, Cees ;
Teng, Y. K. Onno .
RHEUMATOLOGY, 2024, 63 (09) :2387-2398
[49]   Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib [J].
Yvan-Charvet, Laurent ;
Kling, Jelena ;
Pagler, Tamara ;
Li, Hongna ;
Hubbard, Brian ;
Fisher, Tim ;
Sparrow, Carl P. ;
Taggart, Andrew K. ;
Tall, Alan R. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (07) :1430-U405
[50]   Impact of belimumab therapy on the quality of life in patients with systemic lupus erythematosus: A cohort study [J].
Prete, Marcella ;
Susca, Nicola ;
Leone, Patrizia ;
De Giacomo, Andrea ;
Bray, Antonella ;
Brunori, Giuliano ;
Favoino, Elvira ;
Perosa, Federico ;
Racanelli, Vito .
LUPUS, 2023, 32 (13) :1528-1535